



Adverum Biotechnologies to Present at Upcoming Investor Conferences

February 26, 2018

MENLO PARK, Calif., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today that Amber Salzman, Ph.D., president and chief executive officer of Adverum, will present at upcoming investor conferences in March.

Event: Raymond James 39th Annual Institutional Investors Conference
Date: March 5, 2018
Time: 9:15 – 9:45 a.m. ET
Location: Orlando, FL

Event: Cowen and Company 38th Annual Health Care Conference
Date: March 12, 2018
Time: 1:30 – 2:00 p.m. ET
Location: Boston, MA

A live and replay audio webcast of these presentations will be available from Adverum's website at <http://investors.adverum.com>.

About Adverum Biotechnologies, Inc.

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum's core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.

Adverum Contact:

Leone Patterson
Chief Financial Officer
650-665-7222
lpatterson@adverum.com

 [Primary Logo](#)

Source: Adverum Biotechnologies, Inc.